P

PhaseBio Pharmaceuticals, Inc.

32 employees

PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Pharmaceutical
Elastin-like polypeptide biopolymer
Heart failure
improved biotherapeutics
Orphan diseases
DMD cardiomyopathy
Vasoactive Intestinal Peptide
cardiopulmonary disorders
phase transition
Pulmonary Arterial Hypertension
Medical Device
Ticagrelor reversal agent
slow absorption
Medical

Date founded

2002

Funding rounds raised

Total raised

$120M

from 10 investors over 10 rounds

P

PhaseBio Pharmaceuticals, Inc. raised $120M on January 13, 2020

Investors: SFJ Pharmaceuticals, Inc.

P

PhaseBio Pharmaceuticals, Inc. raised $34M on September 5, 2018

Investors: Syno Capital, Fletcher Spaght, Inc. and Mountain Group Partners

P

PhaseBio Pharmaceuticals, Inc. raised $2.8M on February 27, 2018

Investors: National Institutes of Health

P

PhaseBio Pharmaceuticals, Inc. raised $40M on March 12, 2015

Investors: Fletcher Spaght, Inc.

P

PhaseBio Pharmaceuticals, Inc. raised $23M on June 5, 2012

Investors: Astellas Venture Capital L.L.C. and Fletcher Spaght, Inc.

P

PhaseBio Pharmaceuticals, Inc. raised $25M on January 7, 2010

Investors: Fletcher Spaght, Inc.

P

PhaseBio Pharmaceuticals, Inc. raised $6.6M on October 24, 2007

Investors: Fletcher Spaght, Inc.

FAQ